Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections

Surgical Infections

Volumn 9, Issue 1, 2008, Pages 57-66

  Kuti, Joseph L ^a   Dowzicky, Michael ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ARTICLE; CALCULATION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESPONSE; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MONTE CARLO METHOD; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SIMULATION; SKIN INFECTION; SKIN STRUCTURE; STEADY STATE; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE; MODELS, STATISTICAL; MONTE CARLO METHOD; SKIN DISEASES, BACTERIAL;

EID: 41149154301     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.001     Document Type: Article

References (33)

1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-1406.
2. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999: Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20:250-278.
3. Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45:287-293.
4. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect 2005;6:283-295.
5. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-498.
6. Bukharie HA, Abdelhadi MS, Saeed IA, et al. Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen. Diagn Microbiol Infect Dis 2001;40:1-4.
7. Eady EA, Cove JH. Staphylococcal resistance revisited: Community-acquired methicillin-resistant Staphylococcus aureus: An emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-124.
8. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-1444.
9. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29:95-102.
10. Guay DR. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmacother 2004;24:58-68.
11. Zhanel GG, Homenuik K, Nichol K, et al. Glycylcyclines: A comparative review with the tetracyclines. Drugs 2004;64:63-88.
12. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41:S341-353.
13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
14. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a Phase II/III dose for evernimicin and identification of a preclinical breakpoint. Antimicrob Agents Chemother 2001;45:13-22.
15. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003;22:982-992.
16. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram (OPTAMA) Program-North America 2002. Antimicrob Agents Chemother 2004;48:2464-2470.
17. Kuti JL, Ong C, Lo M, et al. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents 2006;28:62-68.
18. Deryke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units during 2004. Pharmacotherapy 2007;27:333-342.
19. Van Wart SA, Owen JS, Ludwig EA, et al. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006;50:3701-3707.
20. Lodise TP Jr, Lomaestro B, Rodvold KA, et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48:4718-4724.
21. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically-ill adults in a medical intensive care unit. Pharmacotherapy 2002;22:1216-1225.
22. Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001;47:421-429.
23. Drusano GL, Plaisance KI, Forrest A, et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:1420-1422.
24. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22.
25. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081.
26. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-2797.
27. Meagher A, Passarell J, Cirincione B, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51:1939-1945.
28. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008;52:204-210.
29. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin/tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind, multicenter study. Clin Infect Dis 2002;34:1460-1468.
30. Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro activity of tigecycline against 3,989 gram-negative and gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005;52:173-179.
31. Sader HS, Jones RN, Stilwell MG, et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-186.
32. Van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-949.
33. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41:S333-S340.